News
Barclays Maintains Overweight on Revolution Medicines, Raises Price Target to $54
18 Jul 24
News, Price Target, Analyst Ratings
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $55
16 Jul 24
News, Price Target, Analyst Ratings
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $55
16 Jul 24
News, Price Target, Analyst Ratings
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
16 Jul 24
News, Short Ideas, Pre-Market Outlook, Markets, Trading Ideas
Microsoft To Rally Around 6%? Here Are 10 Top Analyst Forecasts For Tuesday
16 Jul 24
News, Price Target, Markets, Analyst Ratings, Trading Ideas
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $56
16 Jul 24
News, Price Target, Analyst Ratings
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $62
16 Jul 24
News, Price Target, Analyst Ratings
Barclays Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $52
12 Jul 24
News, Price Target, Initiation, Analyst Ratings
Revolution Medicines Announces Publication In Cancer Discovery Demonstrating Robust Anti-Tumor Activity Of RAS(ON) Inhibitors In Preclinical Models Of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
11 Jul 24
Biotech, News, General
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Jul 24
News, Markets, Movers, Trading Ideas
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
9 Jul 24
News, Intraday Update, Markets, Movers, Trading Ideas
Revolution Medicines To Provide Update On RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program On July 15, 2024 In Investor Webcast
8 Jul 24
Biotech, News, General
Jefferies Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $63
8 Jul 24
News, Price Target, Initiation, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $44 Price Target
13 May 24
News, Price Target, Reiteration, Analyst Ratings
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $46
9 May 24
News, Price Target, Analyst Ratings
Needham Reiterates Buy on Revolution Medicines, Maintains $46 Price Target
9 May 24
News, Price Target, Reiteration, Analyst Ratings
Revolution Medicines Q1 2024 GAAP EPS $(0.70) Beats $(0.75) Estimate
8 May 24
Earnings, Earnings Beats, News
Revolution Medicines Reiterates Projected Full Year 2024 GAAP Net Loss To Be $(480)M-$(520)M
8 May 24
News, Guidance
Press releases
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
11 Jul 24
Health Care, Press Releases
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
8 Jul 24
Press Releases
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)
8 Jul 24
Press Releases
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
5 Jun 24
News, Press Releases
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
8 May 24
Earnings, Press Releases
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
1 May 24
News, Press Releases